共 50 条
Vaccination in children with immune-mediated disorders
被引:1
|作者:
Marinho, Ana Karolina Barreto Berselli
[1
]
机构:
[1] Univ Sao Paulo HCFMUSP, Hosp Clin, Fac Med, Serv Imunol Clin & Alergia, Sao Paulo, SP, Brazil
关键词:
Children with immune-mediated rheumatic;
inflamma-tory diseases;
Live attenuated vaccines;
Non-live" vaccines;
Immunogenicity;
Safety;
JUVENILE IDIOPATHIC ARTHRITIS;
PNEUMOCOCCAL CONJUGATE VACCINE;
RHEUMATIC-DISEASES;
PEDIATRIC-PATIENTS;
VARICELLA VACCINE;
IMMUNOGENICITY;
SAFETY;
TOLERABILITY;
ADOLESCENTS;
IMMUNIZATION;
D O I:
10.1016/j.jped.2022.11.008
中图分类号:
R72 [儿科学];
学科分类号:
100202 ;
摘要:
Objective: To present an updated review of recommendations for the vaccination of children with immune-mediated diseases, with an emphasis on rheumatic and inflammatory diseases.Source of data: Studies published in the PubMed and Scielo databases between 2002 and 2022, Guidelines of Brazilian Scientific Societies, Manuals and Technical Notes of the Ministry of Health of Brazil, on current immunization schedules for special populations. Data synthesis: Immunosuppressive drugs and biological agents reduce the immunogenicity of vaccines and favor susceptibility to infections. The safety and efficacy of immunogens are impor-tant points for vaccination in children with immune-mediated diseases. The safety threshold of a vaccine applied to immunocompromised individuals can be reduced when compared to healthy individuals. Very often, the recommendations for the immunization of children with immune -mediated diseases follow the recommendations for immunocompromised patients. Vaccination against COVID-19, on the other hand, should ideally occur when the disease is stabilized and in the absence of a low degree of immunosuppression. The patients should be informed about the possibility that the immunization may fail during treatment with immunosuppressants. Specific vaccination schedules should be considered to ensure better protection.Conclusions: Recent studies have allowed updating the recommendations on the safety and immu-nogenicity of vaccination in children with immune-mediated diseases, especially for live attenu-ated vaccines. There is a scarcity of data on the safety and efficacy of COVID-19 vaccines in patients, particularly pediatric patients, with rheumatic diseases. The completion of ongoing stud-ies is expected to help guide recommendations on COVID-19 vaccines in this group of patients.(c) 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:S62 / S69
页数:8
相关论文